CONTROVERSIES IN INTERVENTIONAL CARDIOLOGY

Should Genetic Testing Be Done in All Patients Treated With Clopidogrel and Undergoing Percutaneous Coronary Intervention?

CYP2C19 *Genetic Testing Should Not Be Done in All Patients Treated With Clopidogrel Who Are Undergoing Percutaneous Coronary Intervention*

Guillaume Paré, MD, MSc; John W. Eikelboom, MBBS, MSc

Clopidogrel when added to aspirin reduces major vascular events in patients undergoing percutaneous coronary intervention (PCI).[1] Recent reports have suggested that common genetic variants involving hepatic cytochrome P450 system enzymes that convert clopidogrel to its active metabolite are associated with an increased risk of cardiovascular events. Specifically, patients who are carriers of 1 or more loss-of-function *CYP2C19* alleles (including the *2 and *3 alleles) have reduced conversion of clopidogrel to its active metabolite, decreased platelet inhibition, and an increased risk of myocardial infarction, death, and stent thrombosis compared with noncarriers. Based on these findings and on related pharmacokinetic and pharmacodynamic data (NCT01123824), the United States Food and Drug Administration (FDA) has issued a "black box" warning of reduced effectiveness of clopidogrel in patients who are carriers of 2 loss-of-function alleles (so-called poor metabolizers) and has suggested that affected individuals receive a higher dose of clopidogrel or an alternative antiplatelet agent. This warning has led some investigators to conclude that all patients undergoing PCI with planned clopidogrel therapy should undergo *CYP2C19* genetic testing.

> **Response by Sibbing, Bernlochner, and Kastrati on p 521**

In this report, we critically review the evidence for routine *CYP2C19* testing in patients undergoing PCI according to established criteria for the implementation of a screening test in clinical practice.

Summary of the Evidence Linking *CYP2C129* Loss-of-Function Alleles to Clopidogrel Response and Cardiovascular Risk

Clopidogrel is a prodrug that must undergo 2-step hepatic metabolism by enzymes of the CYP system to form the active moiety that inhibits the platelet $P2Y_{12}$ receptor.[2–4] Common loss-of-function variants involving the *CYP2C19* gene have been conclusively demonstrated to influence clopidogrel active metabolite levels and levels of platelet inhibition[5–7] (Figure 1), and an increasing number of clinical reports link loss-of-function alleles with adverse clinical outcomes.[7–12]

Estimates from a meta-analysis[11] of observational studies of patients with coronary artery disease treated with clopidogrel (n=9685), most of whom were undergoing PCI, suggest that carriage of 1 loss-of-function *CYP2C19* allele is

Figure 1. Hypothesized causal chain leading from loss-of-function (LOF) allele carriage to increased ischemic events in clopidogrel-treated patients. CV indicates cardiovascular.

associated with a 1.55-fold increased risk of major adverse cardiovascular events (95% confidence interval, 1.11–2.17; $P=0.01$) and carriage of 2 alleles is associated with a 1.76-fold increase (95% confidence interval, 1.24–2.50; $P=0.002$). However, observational studies are subject to confounding, and because all of the patients included in the meta-analysis were treated with clopidogrel (ie, there was no untreated control group), these data cannot establish whether the increased risk of adverse outcomes linked with carriage of *CYP2C19* loss-of-function alleles is attributable to reduced clopidogrel metabolism or whether it might be mediated through alternative mechanisms that do not involve clopidogrel.

A possible association between *CYP2C19* loss-of-function alleles and cardiovascular risk has also been examined in the context of 3 randomized trials involving acute coronary syndrome (ACS) patients randomly assigned to receive clopidogrel versus placebo (CURE[13]), prasugrel (TRITON[7,14]), or ticagrelor (PLATO[15]), respectively. The main advantage of evaluating the association in the context of a randomized trial is that the design "adjusts" for any impact of *CYP2C19* loss-of-function alleles on outcome that is unrelated to its effect on clopidogrel metabolism. None of the analyses from randomized, controlled trials demonstrated an association between *CYP2C19* loss-of-function alleles and outcome in control patients (ie, patients not treated with clopidogrel), thus providing no evidence that *CYP2C19* predicts outcome independent of its effect on clopidogrel metabolism. However, in analyses involving 5059 patients enrolled in the CURE trial, there was also no evidence that *CYP2C19* loss-of-function alleles modified the benefits of clopidogrel compared with placebo (*P* heterogeneity=0.84), including a separate analysis of 736 patients undergoing PCI with stent insertion (*P* heterogeneity=0.37). Likewise, the analyses from the PLATO trial involving 10 285 ACS patients failed to demonstrate a significant effect of *CYP2C19* loss-of-function alleles on the benefit of ticagrelor compared with clopidogrel (*P* heterogeneity=0.46). Results for patients undergoing PCI have not been separately reported. In contrast with the results of the CURE and PLATO trials, analyses from the TRITON trial demonstrated a nominally significant interaction between *CYP2C19* loss-of-function alleles and treatment with prasugrel compared with clopidogrel (*P* heterogeneity=0.046), a finding that is consistent with a modest impact of the *CYP2C19* loss-of-function allele on outcome in clopidogrel-treated patients.

Pharmacogenetics as a Screening Test
Laboratory testing is often used to screen for conditions in individuals who do not have signs or symptoms of disease.

Before any new screening strategy is adopted, the clinical usefulness of a new screening strategy can be evaluated using the WHO criteria first published by Wilson and Junger in 1968[16] and recently adapted by Mosca.[17] Key criteria are presented in Table 1. The goal of pharmacogenetic testing in patients undergoing PCI is to identify those who are at increased risk of major cardiovascular events and thus might benefit from an alternative antiplatelet treatment. In this respect, pharmacogenetic testing to identify patients who carry 1 or more *CYP2C19* loss-of-function polymorphisms is no different from screening for other conditions. We believe that it is instructive to evaluate *CYP2C19* testing by using the same rigorous criteria.

Critical Evaluation of the Clinical Usefulness of *CYP2C19* Screening in Patients Undergoing PCI
We evaluated the clinical usefulness of *CYP2C19* screening using the criteria presented in Table 1.

Is There a Convenient and Validated Test of *CYP2C19* Genotype?
Validated *CYP2C19* genotyping methods are well established and yield reproducible results with low error rates in the majority of patients. For the present, however, testing for the *CYP2C19* loss-of-function alleles is largely confined to research settings. New technologies that enable rapid testing in the clinic are being developed and could be made available at a reasonable cost if deemed necessary.

Does *CYP2C19* Testing Provide Clinically Significant Prognostic Value Above and Beyond That Provided by Traditional Risk Factors?
CYP2C19 testing appears to provide prognostic value beyond that provided by traditional risk factors, but there is uncertainty about the strength of the association between genotype and clinical outcomes. Estimates of relative risk from individual studies are highly variable, ranging from a 1.5- to 5-fold[8,11] increase in major cardiovascular events associated with carriage of a loss-of-function *CYP2C19* allele. It is unclear to what extent differences in patient presentation

Table 1.   Criteria for the Evaluation of *CYP2C19* Genotype as a Screening Test

Is there a convenient and validated test of *CYP2C19* genotype?

Does *CYP2C19* testing provide clinically significant prognostic value above and beyond that provided by traditional risk factors?

Do we know how to interpret the results of *CYP2C19* testing?

Does intervention that alters the risk factor lead to clinical benefit?

What are the direct and indirect risks of screening?

Table 2.   Meta-Analysis of Effect of Loss-of-Function Carriage on Cardiovascular Death, Myocardial Infarction, or Ischemic Stroke in Studies With >500 Participants

Study	%PCI	LOF Carriers		No LOF Allele		Unadjusted OR (95% CI)	P
		No. of Events	No. at Risk	No. of Events	No. at Risk		
EXCELSIOR[18]	100	5	243	7	554	1.65 (0.47–5.36)	0.53
TRITON[7]	100	46	395	83	1064	1.56 (1.06–2.27)	0.03
FAST-MI[10]	70	63	635	193	1573	0.79 (0.58–1.06)	0.12
RECLOSE[19]	100	15	247	14	525	2.36 (1.11–5.05)	0.03
ISAR[12]	100	55	680	119	1805	1.25 (0.89–1.73)	0.22
Intermountain[11,20]	100	68	344	141	906	1.34 (0.97–1.84)	0.09
PLATO[15]	66	149	1388	332	3516	1.15 (0.94–1.41)	0.18
CURE[13]	15	52	651	179	1886	0.83 (0.60–1.14)	0.27
Overall	73	453	4583	1068	11 829	1.12 (0.99–1.26)	0.06
Overall w/o CURE	83	401	3932	889	9943	1.17 (1.04–1.33)	0.01

PCI indicates percutaneous coronary intervention; LOF, loss of function; OR, odds ratio; and CI, confidence interval.

ORs are unadjusted for clinical covariables. Meta-analysis ORs and *P* values were derived using a fixed-effect model.

(ST-elevation–myocardial infarction versus non–ST-segment elevation–ACS), management strategy (medical versus invasive), timing of administration of clopidogrel, or methods of adjustment for potential confounders accounts for this variability. In most cases, the confidence intervals around the estimates are wide, reflecting the modest numbers of patients and outcome events in the studies. Furthermore, reports of a 5-fold increase in major cardiovascular events associated with a single *CYP2C19* loss-of-function allele are implausible because they suggest that among those who are treated with clopidogrel, carriers of a loss-of-function allele, who comprise approximately one-third of the population, have a net increase in myocardial infarction, stroke, or death compared with noncarriers on placebo.

The magnitude of the association between *CYP2C19* loss-of-function alleles and outcome also varies according to the event. The strongest association appears to be with stent thrombosis, but this is also the least common event, whereas a weaker association exists for myocardial infarction and death.

Collectively, the available data demonstrate a statistically significant association between *CYP2C19* loss-of-function alleles and cardiovascular risk, but the strength of the association is modest and varies according to outcome. A pooled analysis unadjusted for baseline characteristics, restricted to observational cohorts involving at least 500 patients and using a fixed-effects model, yielded an even weaker 1.12-fold increased risk associated with carriage of 1 *CYP2C19* loss-of-function alleles and a 1.22-fold increase in those who carry 2 alleles (Tables 2 and 3). We believe that these estimates are more reliable than those obtained from previous meta-analyses because small trials are subject to greater potential for publica-

tion bias than large trials, and a fixed-effects model avoids a disproportionate effect of small studies on the overall estimate. Unadjusted analyses are more applicable to clinical practice than adjusted analyses because the impact of genotype is generally not adjusted for in clinical practice. It is unclear whether the weak association that we demonstrated between *CYP2C19* loss-of-function alleles and cardiovascular risk is clinically important. Perhaps even more importantly, the lack of impact of the loss-of-function allele on the benefits of clopidogrel compared with placebo in the CURE trial and a similar lack of interaction in the PLATO trial raise questions about the relevance of the results of testing for patient care.

Do We Know How to Interpret the Results of *CYP2C19* Testing?

To be useful for clinicians and patients, the results of a screening test must lend itself to nonambiguous interpretation. In the case of pharmacogenetic testing for clopidogrel, there is still uncertainty as to the genotype at risk. This uncertainty stems in part from the observation that *CYP2C19* loss-of-function allele carriers (ie, individuals carrying either 1 or 2 loss-of-function alleles) are quite frequent in the population but have only modestly increased risk. Poor metabolizers (ie, individuals carrying 2 loss-of-function alleles) have a higher risk but are uncommon, at least in Caucasian populations, where they comprise an estimated 2% of individuals.[11,13,15]

There is also uncertainty on which loss-of-function variants to test. The most common *CYP2C19* loss-of-function polymorphism is the *2 allele, which comprises >99% of all loss-of-function alleles in Europeans. The *3 allele is found in <1% of Europeans but represents >5% of all *CYP2C19* alleles in Asian populations.[21,22] Up to 14% of Chinese have the *2/*2 genotype,

Table 3.   Meta-Analysis of Effect of Carriage of 2 Loss-of-Function Alleles on Cardiovascular Death, Myocardial Infarction, or Ischemic Stroke as Compared With Noncarriers in Studies With >500 Participants

Study	%PCI	2 LOF Alleles		No LOF Allele		Unadjusted OR (95% CI)	P
		No. of Events	No. at Risk	No. of Events	No. at Risk		
TRITON[7]	100	4	38	83	1064	1.44 (0.41–3.73)	0.53
FAST-MI[10]	70	10	58	193	1573	1.51 (0.71–2.91)	0.31
RECLOSE[19]	100	2	26	14	525	3.21 (0.44–12.6)	0.17
ISAR[12]	100	3	47	119	1805	1.01 (0.23–2.83)	1
Intermountain[11,20]	100	3	14	141	906	1.53 (0.33–5.07)	0.47
CURE[13]	15	4	61	178	1880	0.70 (0.20–1.72)	0.65
Overall	73	26	244	728	7753	1.22 (0.80–1.85)	0.36
Overall w/o CURE	91	22	183	550	5873	1.43 (0.90–2.27)	0.13

PCI indicates percutaneous coronary intervention; LOF, loss of function; OR, odds ratio; and CI, confidence interval.

ORs are unadjusted for clinical covariables. Meta-analysis ORs and *P* values were derived using a fixed-effect model.

Adapted with permission from Mega JL et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. *JAMA*. 2010;304:1821–1830. Copyright 2010 American Medical Association. All rights reserved.[11]

but outcomes after PCI do not appear to differ markedly in Asian as compared with Caucasian populations.[23]

Furthermore, an effect of the *CYP2C19* gain-of-function allele (*17) on ischemic[13,24] and bleeding[25] end points has recently been described. The effect of this allele in conjunction with loss-of-function alleles requires further evaluation before the results of *CYP2C19* testing can be properly interpreted.

Does Intervention That Alters the Risk Factor Lead to Clinical Benefit?

Even if a convenient, validated, and readily interpretable test exists that provides clinically significant prognostic value above and beyond that provided by traditional risk factors, it is unlikely to be of value if there are no interventions that can overcome the increased risk of cardiovascular disease associated with a positive test result. Pharmacological studies have shown that a higher dose of clopidogrel or alternative antiplatelet therapies such as prasugrel and ticagrelor provide enhanced platelet P2Y12 receptor inhibition in patients who are poorly responsive to standard doses of clopidogrel[14,15,26,27] and improved clinical outcomes.[28–30] However, enhanced platelet inhibition was also observed in clopidogrel responders, and there is no evidence that a management strategy based on the results of pharmacogenetic or pharmacodynamic testing compared with usual care (without testing) will lead to a benefit for patients.

Several randomized, controlled trials are examining the potential benefits of a management strategy based on the results of routine pharmacogenetic or pharmacodynamic testing compared with usual care (Table 4). The recently completed GRAVITAS trial[32] involved 2214 patients who had undergone PCI with placement of 1 or more drug-eluting stents and failed to demonstrate a benefit of modifying antiplatelet therapy, based on the results of routine pharmacodynamic testing compared with usual care. The trial was powered to demonstrate a 50% reduction in death, myocardial infarction, or stent thrombosis with high-dose compared with standard-dose clopidogrel in patients with high on-treatment platelet reactivity but had unexpectedly low event rates. The TRIGGER-PCI had a planned enrolment of 2150 patients with ACS undergoing PCI but was stopped early because of lower than expected event rates (NCT00910299). If there is a clinical benefit of tailored antiplatelet therapy based on the results of *CYP2C19* testing, it is likely to be evident in patients undergoing PCI who are at high risk of stent thrombosis. However, such patients have multiple other risk factors for stent thrombosis (Table 5[33]), each of which appears to be at least as important as carriage of a *CYP2C19* loss-of-function allele. Premature discontinuation of clopidogrel is the most important potentially modifiable risk factor, associated with a >40-fold increase in risk of stent thrombosis.[33]

An approach that is likely to be more effective and cost-efficient than routine *CYP2C19* testing is to use a newer antiplatelet drug that has been shown in randomized trials to be more effective than standard-dose clopidogrel irrespective of genotype. The PLATO trial[15] showed that ticagrelor is superior to clopidogrel for the prevention of major cardiovascular events, including mortality, in a broad cross section of patients with ACS. There was no net increase in major bleeding with ticagrelor compared with clopidogrel, although ticagrelor increased non–coronary artery bypass graft–related major bleeding. Ticagrelor has already been approved in Europe and could replace clopidogrel across the spectrum of patients with ACS and those undergoing PCI with stent insertion, thereby eliminating the need to consider *CYP2C19* pharmacogenetic testing. There is no need for genotyping if the alternative treatment is superior to standard care irrespec-

Table 4.   Trials Involving at Least 1000 Patients Evaluating Different Management Strategies in Patients With High Residual Platelet Reactivity

Study	Design	No. of Patients	Population	Selection Criterion	Outcome	Follow-Up	Result
ARCTIC (NCT00827411)[31]	Randomized, active-controlled, open-label, multicenter	2466	Stable CAD, elective PCI	Patients after DES randomized to (1) standard-dose clopidogrel plus aspirin (conventional arm) or (2) adjusted-dose clopidogrel plus aspirin based on HRPA (monitoring arm)	Death, nonfatal MI, stroke, urgent TVR, or stent thrombosis	1 y	Ongoing
GRAVITAS[32]	Randomized, placebo-controlled, multicenter	2214	Stable CAD or NSTE ACS undergoing PCI with drug-eluting stent	Patients with HRPA 12 to 24 h after DES randomized to (1) standard 75 mg clopidogrel or (2) high-dose clopidogrel (additional 600 mg followed by 150 mg daily)	CV death, nonfatal MI, or definite/probable stent thrombosis	6 mo	HR, 1.01; 95% CI, 0.58–1.76; $P=0.97$
TRIGGER-PCI (NCT00910299)	Randomized, active-controlled, double-blind, multicenter	2150 (stopped after 432 patients)	Stable CAD, elective PCI	Patients 24 h after DES and 2 to 7 h after clopidogrel and HRPA randomized to (1) prasugrel 60 mg load/10 mg daily or (2) clopidogrel 75 mg daily	CV death or nonfatal MI	6 mo	Stopped early due to lower than expected event rate

ACS indicates acute coronary syndrome; ARCTIC, Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and Interruption Versus Continuation of Double Antiplatelet Therapy; CAD, coronary artery disease; CV, cardiovascular; GRAVITAS, Gauging Responsiveness With A Verify Now Assay-Impact On Thrombosis And Safety; HRPA, high residual platelet activity; MI, myocardial infarction; NSTEMI, non–ST-segment elevation–myocardial infarction; PCI, percutaneous coronary intervention; PI, primary investigator; TRIGGER-PCI, Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel; and TVR, target vessel revascularization.

Adapted and reproduced with permission from Bonello et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. *J Am Coll Cardiol.* 2010;56:919–933.[2]

tive of genetic results. A case for genotyping can only be made if the choice of therapy—standard clopidogrel or an alternative antiplatelet strategy—will differ depending on genotype (Figure 2).

Table 5.   Predictors of Stent Thrombosis

Patient	Hazard Ratios for Stent Thrombosis
Acute coronary syndrome	13.07
Chronic renal failure	7.44
Diabetes mellitus	3.71
Left ventricular ejection fraction	2.99
Antiplatelet therapy	
Discontinuation of antiplatelet therapy	40.96
Stent and procedure	
Bifurcation	5.41
Postprocedural minimal lumen diameter	5.83
Residual dissection	4.45
No. of stents	3.7
Residual thrombus	3.4
Total stent length, per 10 mm	1.12

Adapted and reproduced with permission from Lemesle et al. Stent thrombosis in 2008: definition, predictors, prognosis and treatment. *Arch Cardiovasc Dis.* 2008;101:769–777.[33]

What Are the Direct and Indirect Risks of Screening?

All of the potential costs and consequences of pharmacogenetic testing should be taken into account when considering the potential benefits and risks of *CYP2C19* screening.

The most obvious costs are related to genotyping, which includes the laboratory infrastructure and personnel to provide genetic results with a fast turnaround time, switching to an alternative antiplatelet strategy in affected individuals, and the costs of cardiovascular events prevented and bleeding

Figure 2. Two hypothetical scenarios illustrating situations in which pharmacogenetic testing is or is not of clinical utility. LOF indicates loss of function.

Figure 3. Incidence of ischemic and bleeding events in clopidogrel-treated acute coronary syndrome patients. MACE indicates major adverse cardiovascular events; MI, myocardial infarction.[29]

MACE (11.7%)
MI (6.9%)
Death from vascular causes (5.1%)
Stent thrombosis (1.9%; definite)
Ischemic stroke (1.1%)

Major bleeding (11.2%)
Life-threatening or fatal bleeding (5.8%)
Fatal bleeding (0.3%)

caused by the change in treatment. Pharmacoeconomic considerations are even more important when the risk conferred by carriage of 1 or more *CYP2C19* loss-of-function alleles is small. The cost-effectiveness of implementing routine *CYP2C19* screening is likely to compare unfavorably with alternative strategies such as measures to increase compliance with antiplatelet therapy, the single most important risk factor for stent thrombosis.[33]

The results of testing could also have adverse consequences. For example, an individual labeled as "unresponsive to clopidogrel, based on genes" who is unable to afford the alternative treatment might be tempted to forgo antiplatelet therapy altogether, thereby further increasing the risk of major cardiovascular events.

What Are the Implications for Future Research?

The results of clinical trials comparing management strategies based on the results of routine *CYP2C19* genetic testing with usual care that are currently underway will provide additional insights into the potential benefits and risks of routine testing. In parallel with these studies, however, we urgently require further studies to identify other genetic determinants of response to clopidogrel. Best estimates suggest that the *CYP2C19* loss-of-function alleles account for only 12% of the variability in response to clopidogrel,[9] whereas 72% of the variability is heritable. This implies that most of the variability is accounted for by other as-yet undiscovered genetic factors. We also need reliable estimates of the effect of genetic determinants of response to clopidogrel on different types of ischemic events and on bleeding. Among patients with ACS and/or those undergoing PCI, stent thrombosis is less common but more sensitive to clopidogrel treatment and the potential impact of *CYP2C19* loss-of-function alleles than other outcomes such as myocardial infarction or death. Most cases of stent thrombosis result in myocardial infarction or death, which are counted as major adverse cardiovascular events, but the limitation of using this composite is that the effects of a loss-of-function allele on stent thrombosis could be masked by myocardial infarctions and deaths that are unrelated to stent thrombosis (Figure 3). Even if an effect of *CYP2C19* loss-of-function alleles on stent thrombosis is evident, we also need information on bleeding because it is possible that the increase in stent thrombosis is more than compensated for by a reduction in bleeding.

The highest-quality evidence concerning the impact of genetic testing on patient outcomes is likely to be obtained from appropriately designed, randomized, controlled trials that compare a strategy of modifying treatment, based on the results of genetic screening with standard care. Such trials will not only provide reliable estimates of the effect of genotype on drug response but will also take into account the potential impact of the testing procedure itself on patient outcomes. For example, implementation of genetic testing in real-life settings (as opposed to retroactive analysis of stored samples) could delay administration of effective antiplatelet therapies and thereby compromise patient outcomes.

Conclusion

The role of *CYP2C19* loss-of-function alleles in determining the pharmacokinetics and pharmacodynamics of clopidogrel has been clearly demonstrated, and there is convincing evidence that *CYP2C19* loss-of-function alleles are associated with adverse outcomes. However, uncertainty remains about the strength of association and the impact of *CYP2C19* loss-of-function alleles on the net clinical benefit of clopidogrel treatment. Perhaps, most importantly, we do not know whether a treatment strategy based on the results of routine laboratory screening for *CYP2C19* loss-of-function alleles improves patient outcome compared with usual care. In the absence of this information, we cannot support recommendations for mandatory testing of patients undergoing PCI.

We accept that it is not realistic to mandate a randomized, controlled trial for every genetic variant that is implicated as a modulator of drug action.[34] However, in the case of *CYP2C19* loss-of-function alleles, the best estimates that are currently available suggest that the effect of these alleles is so small that their impact can only be reliably quantified by using randomization to minimize the impact of potential confounders. If such trials are deemed worthwhile, it is imperative that they are adequately powered to avoid inconclusive results such as those obtained in the recently completed GRAVITAS trial and the prematurely discontinued TRIGGER-PCI trial.

Additional studies are also required to identify as-yet undiscovered genetic variants that could play a much more important role than *CYP2C19* in determining response to clopidogrel. Any future genetic treatment algorithms must

also take into account the role of "traditional" risk factors in determining whether patients who are carriers of a *CYP2C19* loss-of-function allele will benefit from alternative platelet therapies.

Despite our cautionary tone concerning the routine implementation of *CYP2C19* for patients undergoing PCI, we believe that the future is bright for genetic testing. First, additional trials that are underway will help to resolve uncertainly about the clinical usefulness of *CYP2C19* testing and will also serve to define the optimal approach to addressing questions of this nature in the future. Second, as the genetic architecture of clopidogrel response is elucidated and a higher fraction of the predicted heritability is accounted for, genetic testing that incorporates *CYP2C19* testing will almost certainly gain in importance among patients who will be treated with clopidogrel. Finally, advances in testing technologies and informatics are expected to make the results of complete genetic testing more widely available in the general population, thereby assisting physicians to select the most appropriate antiplatelet therapy for individual patients without awaiting the results of additional laboratory testing.

Disclosures

Dr Paré is a member of the Thrombosis and Atherosclerosis Research Institute and has received honoraria from Sanofi and Bristol-Myers Squibb. Dr Eikelboom has received honoraria and research support from companies that develop and market existing and new antiplatelet drugs including Astra-Zeneca, Bayer, Bristol-Myers-Squibb, Eli-Lilly, and Sanofi.

References

1. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. *Lancet*. 2001;358:527–533.
2. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, Van Werkum JW, Paganelli F, Price MJ, Waksman R, Gurbel PA. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. *J Am Coll Cardiol*. 2010;56:919–933.
3. Hagihara K, Kazui M, Kurihara A, Yoshiike M, Honda K, Okazaki O, Farid NA, Ikeda T. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. *Drug Metab Dispos*. 2009;37:2145–2152.
4. Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, Ikeda T, Kurihara A. Identification of the human cytochrome p450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. *Drug Metab Dispos*. 2010;38:92–99.
5. Jeong YH, Kim IS, Park Y, Kang MK, Koh JS, Hwang SJ, Kwak CH, Hwang JY. Carriage of cytochrome 2c19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study. *J Am Coll Cardiol Cardiovasc Interv*. 2010;3:731–741.
6. Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS II, Lachno DR, Salazar D, Winters KJ. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmaco-

7. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. Cytochrome p-450 polymorphisms and response to clopidogrel. *N Engl J Med*. 2009;360:354–362.
8. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, Bensimon G, Funck-Brentano C, Montalescot G. Cytochrome p450 2c19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. *Lancet*. 2009;373:309–317.
9. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W, Gurbel PA. Association of cytochrome p450 2c19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. *JAMA*. 2009;302:849–857.
10. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, Steg PG, Ferrieres J, Danchin N, Becquemont L. Genetic determinants of response to clopidogrel and cardiovascular events. *N Engl J Med*. 2009;360:363–375.
11. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. *JAMA*. 2010;304:1821–1830.
12. Sibbing D, Stegherr J, Latz W, Koch W, Mehilli J, Dorrler K, Morath T, Schomig A, Kastrati A, von Beckerath N. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. *Eur Heart J*. 2009;30:916–922.
13. Pare G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Hirsh J, Simonsen K, Bhatt DL, Fox KA, Eikelboom JW. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. *N Engl J Med*. 2010;363:1704–1714.
14. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias WL, Braunwald E, Sabatine MS. Cytochrome p450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. *Circulation*. 2009;119:2553–2560.
15. Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, Husted S, Katus H, Steg PG, Shah SH, Becker RC. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. *Lancet*. 2010;376:1320–1328.
16. Wilson JMG, Jungner G. *Public health papers no. 34. principles and practice of screening for disease.* WHO Chronicle Geneva: World Health Organization. 1968;22:473.
17. Mosca L. C-reactive protein: to screen or not to screen? *N Engl J Med*. 2002;347:1615–1617.
18. Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, Stratz C, Schmiebusch P, Bestehorn HP, Buttner HJ, Neumann FJ. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. *J Am Coll Cardiol*. 2008;51:1925–1934.
19. Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, Buonamici P, Antoniucci D, Abbate R, Gensini GF. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. *Am J Cardiol*. 2009;103:806–811.
20. Anderson JL, Mower CP, Horne BD, Muhlestein JB, Park JJ, Bair TL, Carlquist JF. Carriage of the CYP2C19*2 allele increases one-year risk of myocardial infarction among recipients of drug-eluting stents treated with clopidogrel. *J Am Coll Cardiol*. 2009;53:A1–A99.
21. Hwang SJ, Jeong YH, Kim IS, Koh JS, Kang MK, Park Y, Kwak CH, Hwang JY. The cytochrome 2c19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention. *Thromb Res*. 2011;127:23–28.
22. Rosemary J, Adithan C. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. *Curr Clin Pharmacol*. 2007;2:93–109.
23. Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed

warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association, endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. *J Am Coll Cardiol*. 2010;56:321–341.

24. Tiroch KA, Sibbing D, Koch W, Roosen-Runge T, Mehilli J, Schomig A, Kastrati A. Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. *Am Heart J*. 2010;160:506–512.

25. Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, Morath T, Schomig A, von Beckerath N, Kastrati A. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. *Circulation*. 2010;121:512–518.

26. Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R, Rasmussen L, Storey RF, Nielsen T, Eikelboom JW, Sabe-Affaki G, Husted S, Kereiakes DJ, Henderson D, Patel DV, Tantry US. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. *Circulation*. 2010;121:1188–1199.

27. Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, Naganuma H, Siegbahn A, Wallentin L. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. *Eur Heart J*. 2006;27:1166–1173.

28. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM. Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 2007;357:2001–2015.

29. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsen M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 2009;361:1045–1057.

30. Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, Granger CB, Jolly S, Joyner CD, Rupprecht HJ, Widimsky P, Afzal R, Pogue J, Yusuf S. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. *N Engl J Med*. 2010;363:930–942.

31. Collet JP, Cayla G, Cuisset T, Elhadad S, Range G, Vicaut E, Montalescot G. Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel after des implantation, and (2) treatment interruption versus continuation, 1 year after stenting (ARCTIC) study. *Am Heart J*. 2011;161:5e15–12e15.

32. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillablower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. *JAMA*. 2011;305:1097–1105.

33. Lemesle G, Delhaye C, Bonello L, de Labriolle A, Waksman R, Pichard A. Stent thrombosis in 2008: definition, predictors, prognosis and treatment. *Arch Cardiovasc Dis*. 2008;101:769–777.

34. Roden DM, Wilke RA, Kroemer HK, Stein CM. Pharmacogenomics: the genetics of variable drug responses. *Circulation*. 2011;123:1661–1670.

Response to Paré and Eikelboom

Dirk Sibbing, MD; Isabell Bernlochner, MD; Adnan Kastrati, MD

Drs Paré and Eikelboom provide a very contemplative commentary and sound a note of caution in relation to *CYP2C19* genetic testing in clopidogrel-treated patients. They present the results of their own meta-analysis on the effect of *CYP2C19*2* allele carriage on cardiovascular death, myocardial infarction, or stroke. While finding only a modest association for this combined end point, they state that the strongest association of *2 appears to be with stent thrombosis, an end point that Paré and Eikelboom did not analyze. The authors' assertion that the advent of ticagrelor may deem genotyping unnecessary is debatable. High-potency P2Y12 receptor blockers such as prasugrel or ticagrelor have been evaluated for their safety and efficacy profiles only in acute coronary syndrome patients thus far. However, the majority of patients undergoing coronary stenting are in a stable condition, and it may well be that in these patients, the balance between the reduction of ischemic events and the induction of bleeding is unfavorable. Moreover, the history of clopidogrel, with about a decade needed after its approval to really understand the pharmacokinetic and pharmacodynamic properties, has taught us to show a healthy mistrust when new and promising drugs are introduced. In this context, just recently, a first report on high on-treatment platelet reactivity with prasugrel has set the stage to study these newer drugs more thoroughly. A short while ago, when clopidogrel was the single choice of treatment available to sufficiently inhibit platelets with an acceptable safety profile, there was much less need for genotyping or phenotyping to individualize treatment regimens. Nowadays, however, the armamentarium of drugs that target the P2Y12 platelet receptor is rapidly increasing. It is now also left to the decision of the attending physician which drug to choose for the individual patient in the respective setting, and this with the primary aim to balance the risk of thrombotic and bleeding events. With different treatment options available now, more guidance to tailor antiplatelet treatment is surely necessary. Genotyping alone or, even better, in combination with platelet function testing to assess the level of P2Y12 receptor inhibition, will help us to sort out the best drug for the individual patient.

Circulation
Cardiovascular Interventions

American Heart Association.

CYP2C19 **Genetic Testing Should Not Be Done in All Patients Treated With Clopidogrel Who Are Undergoing Percutaneous Coronary Intervention**
Guillaume Paré and John W. Eikelboom

The online version of this article, along with updated information and services, is located on the
World Wide Web at:

http://circinterventions.ahajournals.org/content/4/5/514